Researchers have discovered a new way to optimize results in treating patients with prostate cancer tumors while minimizing negative side effects. The study is featured in the November issue of the Journal of Nuclear Medicine.
According to the Centers for Disease Control, "Aside from non-melanoma skin cancer, prostate cancer is the most common cancer among men in the United States. It is also one of the leading causes of cancer death among men of all races."
Prostate-specific membrane antigen (PSMA) is an important target for nuclear medicine imaging of prostate cancer and subsequent PSMA-targeted radionuclide therapy. This combination of diagnostic imaging and therapy targeted on a feature of the identified tumors is called theranostics. The aim of this study was to evaluate the change in the whole-body distribution of the imaging agent fluorine-18 (18F)-PSMA-1007 when solutions with different peptide concentrations are used.
For the study, a mouse xenograft model was used, with the mice divided into three groups according to the peptide concentration injected (high, medium and low concentration/molar activity levels). A decrease in the peptide concentration (or molar activity) level resulted in decreased uptake in the tumor and, to a greater degree, in the salivary glands.
"This study demonstrated that the salivary glands, a risk organ in [actinium-225] 225Ac-PSMA therapy, showed more sensitive decrease in uptake against a reduced molar activity level of the radioligand solution than the tumors," explains Fumihiko Soeda in the Department of Nuclear Medicine and Tracer Kinetics at the Osaka University Graduate School of Medicine in Osaka, Japan. "This suggests that molar activity is an essential factor to define the optimal distribution for theranostic compounds. There is a possibility of obtaining a therapeutic effect in the tumor while minimizing the adverse effects in the salivary glands by setting an appropriate molar activity level in PSMA-targeted therapy."
This study was partly supported by collaborative research funds from Nihon Medi-Physics Co., Ltd., Japan.
The authors of "Impact of 18F-PSMA-1007 Uptake in Prostate Cancer Using Different Peptide Concentrations: Preclinical PET/CT Study on Mice," include Fumihiko Soeda, Tadashi Watabe, Yuwei Liu, Genki Horitsugi, Eku Shimosegawa, and Jun Hatazawa, Osaka University Graduate School of Medicine, Osaka, Japan; Sadahiro Naka and Mitsuaki Tatsumi, Osaka University Hospital; Oliver C. Neels, German Cancer Research Center, Heidelberg, Germany; Klaus Kopka, German Cancer Research Center and the German Cancer Consortium, Heidelberg; and Frederik L. Giesel, University Hospital Heidelberg and the German Cancer Consortium.
Please visit the SNMMI Media Center for more information about molecular imaging and precision medicine. To schedule an interview with the researchers, please contact Rebecca Maxey at (703) 652-6772 or email@example.com. Current and past issues of the Journal of Nuclear Medicine can be found online at http://jnm.snmjournals.org.
About The Journal of Nuclear Medicine
The Journal of Nuclear Medicine (JNM) is the world's leading nuclear medicine, molecular imaging and theranostics journal, accessed more than 9 million times each year by practitioners around the globe, providing them with the information they need to advance this rapidly expanding field.
JNM is published by the Society of Nuclear Medicine and Molecular Imaging (SNMMI), an international scientific and medical organization dedicated to advancing nuclear medicine and molecular imaging--precision medicine that allows diagnosis and treatment to be tailored to individual patients in order to achieve the best possible outcomes. For more information, visit http://www.snmmi.org.
Journal of Nuclear Medicine